• <strike id="xmwty"><table id="xmwty"></table></strike>
    <progress id="xmwty"></progress>

      <b id="xmwty"></b>

      ×

      Tonghua Dongbao announces NMPA acceptance of its clinical trial application for oral small-molecule GLP-1 receptor agonist (THDBH110 Capsules)

      Date:2023-08-22
      Author:東寶
      Views:1

      Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") received a notice of acceptance (No. CXHL2300887) from the Center for Drug Evaluation of the National Medical Products Administration (NMPA) for the clinical trial of the oral small-molecule GLP-1 receptor agonist (THDBH110 Capsules).

       

      The glucagon-like peptide 1 (GLP-1) receptor is a prominent target for treating type 2 diabetes and obesity. GLP-1 receptor agonists have significant therapeutic potential and market reach. Accordingly, the Company is advancing the development of various GLP-1 receptor agonists, including liraglutide injections, dual GLP-1/GIP receptor agonists, and oral small-molecule GLP-1 receptor agonists.

       

      About THDBH110 Capsules

      GLP-1 receptor agonists on the market are injections, made up of large molecules or polypeptides, with less-than-satisfactory medication adherence. The Company's THDBH110 is an oral, small-molecule alternative. Preclinical results show that the THDBH110 capsule is highly bioavailable and effective in reducing glucose levels and weight. This product not only provides a new treatment option for lowering glucose, reducing weight, and protecting cardiovascular system for type 2 diabetes and obesity patients, but also improves medication convenience and adherence. To date, no oral small-molecule GLP-1 receptor agonists have been approved globally.

       

      As an effective hypoglycemic agent, GLP-1 receptor agonists have a promising market outlook. China ranks first globally in the number of diabetes patients, with around 140 million adult patients as per 2021 data from the International Diabetes Federation (IDF). The demand for GLP-1 receptor agonist drugs is surging. According to data from Menet.com, in 2022, the sales of GLP-1 receptor agonist drugs in Chinese public medical institutions and urban brick-and-mortar pharmacies, reached nearly RMB 6 billion, a year-on-year growth of over 100%.

       

      GLP-1 receptor agonists, with their notable weight loss benefits and controllable side effects, are a primary recommendation in international obesity treatment guidelines. Overweight and obesity are associated with severe health risks, such as cardiovascular diseases, diabetes, and musculoskeletal disorders. As China's guidelines for treating obesity gradually align with international standards, the potential for GLP-1 receptor agonists in weight loss treatments is immense.

       

      The clinical trial acceptance of THDBH110 marks a significant step for the Company in the R&D of GLP-1 receptor agonists. We will advance our R&D swiftly and efficiently to provide patients with more effective and safe GLP-1 receptor agonist options.


      0 国产在线看片av免费,91中文字幕 国产,国产丝袜脚足j在线视频播放,黄视频在线观看无码免费
    1. <strike id="xmwty"><table id="xmwty"></table></strike>
      <progress id="xmwty"></progress>

        <b id="xmwty"></b>

        亚洲 自拍 另类小说综合图区| 制服丝袜欧美久久| 91久久精品日日躁夜夜躁欧美| 欧美v国产在线一区二区三区| 久久精品女人毛片水多国产| 国产91一区二区在线播放| 99久久免费精品视香蕉蕉| 亚洲综合网伊人中文| 亚洲国产精品无码久久青草| 午夜无码区在线观看亚洲| 无码中出爆乳一区| 亚洲中文字幕av在线| 久久亚洲精品成人无码网站| 精品无码国产免费| 中文成人无字幕乱码精品区| 亚洲国产成人资源在线| 国产在线观看精品无码尤物| 久久国产精品免费视频| 久久久综合香蕉尹人综合网| 日本第一福利片在线观看中文| 人妻在线视频无码专区| 色婷婷五月在线精品| 制服丝袜无码专区亚洲| 国产福利在线观看视频| 亚洲女同中文字幕| 亚洲V国产V日韩V欧美V| 99中文字幕久久| 亚洲中文av一区二区三区| 亚洲一区二区三区不卡国产_亚洲|